<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="227025">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00126438</url>
  </required_header>
  <id_info>
    <org_study_id>MBG312</org_study_id>
    <nct_id>NCT00126438</nct_id>
  </id_info>
  <brief_title>Meta-Iodobenzylguanidine (123I-mIBG) Scintigraphy Imaging in Patients With Heart Failure and Control Subjects Without Cardiovascular Disease</brief_title>
  <official_title>An Open-Label, Multicenter, Phase 3 Study Evaluating the Prognostic Usefulness of I-123 mIBG Scintigraphy for Identifying Subjects With Heart Failure Who Will Experience an Adverse Cardiac Event</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>GE Healthcare</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>GE Healthcare</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The study is designed to study the utility of 123I-mIBG as a diagnostic imaging agent to
      predict cardiac outcome in subjects with heart failure and in comparison to subjects without
      cardiovascular disease.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase 3, open-label, multicenter trial to investigate the prognostic usefulness of
      123I-mIBG imaging to identify those subjects with New York Heart Association (NYHA) Class II
      and III HF who will experience an adverse cardiac event. The study will consist of a maximum
      of 587 subjects (525 HF subjects and 62 control subjects) administered 123I-mIBG at
      approximately 40 centres in the United States. Subject status will be monitored at 6-week
      intervals post-administration of 123I-mIBG to assess the occurrence of adverse cardiac
      events. The median follow-up is expected to be 9 months.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>July 2005</start_date>
  <completion_date type="Actual">September 2008</completion_date>
  <primary_completion_date type="Actual">July 2008</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>Open Label</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Assessment of myocardial sympathetic innervation (as either normal or abnormal) for identifying risk of adverse cardiac event.</measure>
    <time_frame>24 months or confirmation of 56 adverse cardiac events</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Assessment of myocardial sympathetic innervation (numerical H/M ratio) for identifying risk of adverse cardiac event.</measure>
    <time_frame>24 months or confirmation of 56 adverse cardiac events</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Quantitative myocardial 123I-mIBG uptake to identify HF subjects at higher risk of earlier HF progression, potentially fatal ventricular arrhythmias, or cardiac death.</measure>
    <time_frame>24 months or confirmation of 56 adverse cardiac events</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Modeling to predict risk for adverse cardiac events.</measure>
    <time_frame>24 months or confirmation of 56 adverse cardiac events</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety profile</measure>
    <time_frame>24 hours post dose</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">515</enrollment>
  <condition>Heart Failure, Congestive</condition>
  <arm_group>
    <arm_group_label>123I-mIBG (meta-iodobenzylguanidine)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>123I-mIBG (meta-iodobenzylguanidine)</intervention_name>
    <description>Single Dose</description>
    <arm_group_label>123I-mIBG (meta-iodobenzylguanidine)</arm_group_label>
    <other_name>MIBG</other_name>
    <other_name>I123</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Study subjects must be adults with an established diagnosis of heart failure (New
             York Heart Association Class II or III) and reduced left ventricular ejection
             fraction (LVEF) (&lt; 35%) or be healthy volunteers without heart disease.

        Exclusion Criteria:

          -  Healthy volunteers are not eligible if they have a history diabetes mellitus,
             signs/symptoms of neurological disease (eg, Parkinson's Disease, multiple system
             atrophy, Parkinsonian syndromes), or other diseases known to affect the sympathetic
             nervous system.

          -  Subjects with New York Heart Association Class I or IV heart failure are not
             eligible.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>John Strohmeyer</last_name>
    <role>Study Director</role>
    <affiliation>GE Healthcare</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>GE Healthcare</name>
      <address>
        <city>Princeton</city>
        <state>New Jersey</state>
        <zip>08540</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <lastchanged_date>December 2, 2009</lastchanged_date>
  <firstreceived_date>August 3, 2005</firstreceived_date>
  <responsible_party>
    <name_title>Arnold Jacobson, M.D.</name_title>
    <organization>GE Healthcare</organization>
  </responsible_party>
  <keyword>Heart Failure</keyword>
  <keyword>nuclear cardiology</keyword>
  <keyword>sympathetic innervation</keyword>
  <keyword>123I-mIBG</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Heart Failure</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>3-Iodobenzylguanidine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
